GRI Bio Inc. (GRI NASDAQ) stock market data APIs
$2.3577
-0.01(-0.4%)
as of May 6, 2026
Try our APIs with
free plan!
GRI Bio Inc. Financial Data Overview
Price chart is built with
Anychart
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Prev. Close
2.3577
Open
2.3446
High
2.4011
Low
2.211
52 wk Range
2.1-80.36
Market Cap
3 381 K
Shares Outstanding
1 445 K
EPS
-116.61
Beta
-0.769
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GRI Bio Inc. data using free add-ons & libraries
Get GRI Bio Inc. Fundamental Data
GRI Bio Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -11 973 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-01-30
- EPS/Forecast: -29.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GRI Bio Inc. News
New
How The Grainger (LSE:GRI) Investment Story Is Evolving As The Narrative Holds Steady
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Analysts have kept their pr...
3 Undervalued Small Caps In Global With Recent Insider Activity
In a week marked by geopolitical tensions and fluctuating energy prices, global markets experienced mixed results, with small-cap indices like the S&P MidCap 400 and Russell 2000 showing resilience by...
3 Promising Undervalued Small Caps In European Markets With Insider Buying
Amid renewed trade and geopolitical uncertainty, European markets have seen a downturn, with the pan-European STOXX Europe 600 Index ending 0.98% lower. Despite this challenging environment, business ...
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio...
Get GRI Bio Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
